ProBioGen Grows by 50 Percent in Last Two Years
Susanne Kaestner and Thea Boehm Join Biopharma Company’s Team
Berlin, Germany - June 2, 2022
The Berlin-based biopharmaceutical enterprise ProBioGen has increased its staff by 50 percent since April 2020. More than 250 "ProBioGeniuses", as employees are known internally, now work in the company's three locations in Berlin. Reflecting this growth, ProBioGen has filled two strategic important positions: Susanne Kaestner joins the company as Senior Vice President, Quality and member of the Executive Team, and Dr. Thea Boehm as Vice President, Business Development (BD).
Susanne Kaestner heads ProBioGen's enlarged and restructured quality department. She has over 20 years' experience in quality and regulatory affairs. "Combing the quality assurance and quality control departments into one and linking it to the executive team allows ProBioGen to follow its strategy of offering its customers a full-service package," Kaestner said. "Especially in times of strong growth, the quality department helps to ensure that our customers continue to have the necessary confidence in the good manufacturing processes at ProBioGen and keep coming back. I am very excited about contributing to ProBioGen's growth and continuously developing and improving quality processes."
Dr. Thea Boehm leads the growing, globally active business development team. With her long track record of building lasting relationships in the industry she will drive the expansion of ProBioGen's global customer base. Especially with her strong background in cell and gene therapy (CGT) she will strengthen it - for premium vector technology and services to efficiently produce biologics in the field of proteins and CGT. She has a doctorate in human sciences and immunology and 20 years' experience in the CGT environment, managing clinical studies, clinical and commercial BD.
"Thea is a perfect fit to focus on ProBioGen's clients as part of our vertical and horizontal growth strategy," said Dr. Gabriele Schneider, Chief Business Officer of ProBioGen. "She has significant experience in successfully conducting business in the life sciences industry and the important understanding that partnerships and client satisfaction are key."
"I am thrilled to welcome Susanne and Thea to our company’s inspiring journey," said Dr. Lutz Hilbrich, ProBioGen's Chief Executive Officer. "We envision a world in which no one has to fear getting sick. With our excellent services and technologies we contribute to make this vision more and more reality. We enable our customers to succeed with their innovative new drugs and vaccines. Encouraged by their strong demand we intend to grow sustainably in order to help more and more clients and hence ultimately patients. This requires our processes, technologies and products to be of highest quality."
ProBioGen is a Berlin-based specialist for developing and manufacturing complex therapeutic glycoproteins. Combining both state-of-the-art development services, based on ProBioGen's CHO.RiGHT® expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties. Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen has been operational for more than 25 years. At two locations in Berlin, more than 250 employees contribute to the creation of new therapies in medicine worldwide through their creative and meticulous work.
Dr. Gabriele Schneider
Chief Business Officer